US Executive Compensation Proxy SEC Filings — June 05, 2026

Pro forma revenue of $7.5M for FY2025 with a net loss of $68.4M, implying a negative net profit margin of -912%. The merger closed March 19, 2026, but pro forma adjustments are preliminary and subject to change, creating uncertainty. The VIE structure of Corvex OpCo indicates high financial risk.

Pro forma net loss per share of $(33.53) for FY2025 and $(7.81) for Q1 2026 shows a sequential improvement trend (loss per share declining), but the absolute losses remain severe. The Exchange Ratio of 2.2255 suggests a significant dilution event for existing shareholders.

Reverse stock split proposal (1-for-5 to 1-for-25) directly signals Nasdaq listing compliance risk. With 38,978,693 shares outstanding, a 1-for-25 split would reduce shares to ~1.56M, potentially improving per-share metrics but risking negative market perception and dilution concerns.

Proposal to increase authorized common stock from 166,666,667 to 500,000,000 shares (200% increase) following a 1-for-3 reverse split effective March 9, 2026. This dual action (reverse split + share increase) is a strong signal of future dilution to fund operations, typical of cash-burning biotechs.

The SPAC merger with IQM involves a complex capital restructuring with a Share Split Factor based on 180,000,000 divided by pre-split shares. The conversion of RAAQ Class B shares and warrant assumption by IQM creates potential for value creation if IQM's underlying business is strong, but no financials are provided.

Election of nine VA-1 Managers, including two new nominees to replace retiring managers, indicates governance continuity. The large vote base (1.42B votes eligible) and low quorum requirement (10%) suggest low retail engagement, typical of institutional structures.

Similar to TIAA, the election of nine trustees with two new nominees signals stable governance. The virtual meeting format (July 21, 2026) and standard voting procedures offer no actionable alpha signals.

The VIE determination for Corvex OpCo means Movano may have to consolidate Corvex's financials, potentially exposing it to off-balance-sheet risks. This is a red flag for investors seeking transparency.

Pro forma net loss of $68.4M for FY2025 on only $7.5M revenue, with a net loss per share of $(33.53). The company is burning cash at an alarming rate, and the VIE structure adds complexity to financial reporting.

The reverse stock split proposal (1-for-5 to 1-for-25) is a direct response to Nasdaq listing compliance. If the split fails to maintain the minimum bid price, the stock could be delisted, leading to liquidity collapse.

The proposal to increase authorized shares by 200% (from 166.7M to 500M) following a reverse split suggests the company plans significant future equity issuances. This could massively dilute existing shareholders, especially given only 2.85M shares outstanding post-split.

The pro forma adjustments are explicitly stated as 'preliminary and subject to material change.' Investors relying on the $7.5M revenue or $68.4M loss figures may face significant revisions, creating earnings risk.

The DEFM14A provides no financial performance metrics for IQM, the target company. This lack of transparency makes it impossible to assess the merger's value proposition, increasing execution risk.

Reverse stock splits are often viewed negatively by the market as a sign of distress. The Board's decision to set the exact ratio later introduces uncertainty, which could lead to selling pressure ahead of the June 25, 2026 meeting.

With only 2,848,540 shares outstanding post-reverse split, the stock is highly susceptible to price volatility from small trades. The 35% quorum requirement (997,000 shares) may be difficult to achieve, risking meeting adjournment.

The quorum requirement of only 10% (142M out of 1.42B votes) means decisions can be made with minimal participation, potentially disenfranchising smaller contractowners.

The merger with Corvex OpCo closed on March 19, 2026, and the Exchange Ratio of 2.2255 provides a clear conversion metric. If the combined company's fundamentals improve (e.g., revenue growth from $7.5M), the current pro forma loss could narrow, offering upside.

If the reverse stock split (1-for-5 to 1-for-25) is approved on June 25, 2026, the reduced share count could attract institutional investors who avoid sub-$1 stocks. The Board's flexibility on the ratio allows for optimization, potentially boosting per-share metrics.

The 200% increase in authorized shares could be used for acquisitions, partnerships, or licensing deals. If Artelo announces a promising pipeline development, the dilution could be offset by value creation.

The merger with IQM, while lacking financials, could unlock value if IQM has strong growth prospects. The warrant assumption by IQM provides optionality for warrant holders, and the Share Split Factor mechanism may benefit early investors.

The election of two new managers alongside seven incumbents suggests a managed transition. For long-term contractowners, this stability reduces governance risk, making the VA-1 a safe harbor in volatile markets.

Similar to TIAA, the unanimous Board recommendation for trustee election signals strong governance. Participants can vote with confidence, and the virtual meeting format (July 21, 2026) ensures accessibility.

Pro forma revenue of $3.7M in Q1 2026 annualizes to ~$14.8M, compared to $7.5M in FY2025, implying a potential 97% YoY growth rate. If this trend continues, the net loss could shrink faster than expected.

Curis Inc. and Artelo Biosciences both propose reverse stock splits and share increases to maintain listing and fund operations. This pattern is common among cash-strapped biotechs with no approved products, indicating sector-wide liquidity pressure. Investors should scrutinize cash runway and pipeline milestones.

Real Asset Acquisition Corp.'s merger with IQM involves a multi-step capital restructuring (share splits, warrant conversions, ADS issuance) typical of SPAC deals. The lack of financial disclosure highlights the opacity risk in SPAC targets, requiring deep due diligence.

TIAA Separate Account VA-1 and CREF both feature manager/trustee elections with two new nominees replacing retirees. This suggests a deliberate succession planning process in large institutional funds, reducing governance disruption risk for long-term holders.

Movano Inc.'s merger with Corvex OpCo, including a VIE determination and pro forma adjustments, exemplifies the accounting complexity in M&A. The preliminary nature of financials (subject to material change) is a common theme that investors must monitor post-close.

All six filings utilize virtual-only shareholder meetings (via webcast or proxyvote.com), reflecting a post-pandemic norm. This reduces costs but may lower engagement, as seen in low quorum requirements (10% for TIAA). Investors should ensure they register early to vote.

Three of six filings (Curis, Artelo, Movano) involve significant capital structure changes (reverse splits, share increases, merger exchanges). This theme indicates that small-cap companies are actively managing their equity to survive, often at the expense of existing shareholders.

June 25, 2026 - Stockholders vote on reverse stock split (1-for-5 to 1-for-25). Watch for the Board's chosen ratio and post-meeting price action. If the split is approved, monitor Nasdaq compliance and potential institutional buying.

July 17, 2026 - Vote on increasing authorized shares to 500M. Watch for any pre-meeting announcements of pipeline updates or partnerships that could justify the dilution. Also monitor the stock's liquidity given the low share count.

Expected late July/August 2026 - First full quarter post-merger with Corvex OpCo. Watch for actual revenue vs. pro forma estimates ($3.7M in Q1 2026) and any revisions to the preliminary financials. The VIE consolidation impact will be key.

July 21, 2026 - Election of nine VA-1 Managers. Watch for any dissident manager campaigns or significant vote against recommendations, which could signal governance issues.

July 21, 2026 - Election of nine trustees. Similar to TIAA, monitor for any governance challenges or changes in board composition that could affect fund management.

Date TBD - The merger with IQM requires shareholder approval. Watch for the definitive vote date and any material changes to the Share Split Factor or warrant terms. Post-close, monitor IQM's financial disclosures for the first time.

The 1-for-3 reverse split effective March 9, 2026, may cause short-term volatility. Watch for any Nasdaq compliance issues or further capital raises given the authorized share increase proposal.

No insider transactions reported in the filing, but post-merger, watch for insider buying or selling by Corvex OpCo management. Significant insider sales could signal lack of confidence in the combined entity.